The UK medicines wholesale sector continues to operate under active regulatory oversight.
Recent MHRA updates confirm that inspections remain risk-based, meaning organisations may be inspected on-site or remotely depending on their risk profile, with outcomes that can include restrictions or changes to GDP certification.
This is not a one-off process.
It is an ongoing expectation.
GDP Compliance Is Not Static
A common misunderstanding is that once a business has systems in place, those systems remain acceptable indefinitely.
In practice, compliance needs to be maintained, reviewed and evidenced continuously.
GDP is about ensuring that medicines are consistently stored, handled and distributed under appropriate conditions throughout the supply chain.
If those controls weaken, the risk increases.
What Recent Findings Are Showing
Across 2025 and into 2026, inspection and compliance trends continue to highlight recurring issues.
These include:
- Weak data integrity and access control
- Poorly defined user roles in quality systems
- Gaps in temperature monitoring and cold chain oversight
- Supply to unauthorised or insufficiently verified recipients
- Inadequate documentation or record-keeping
- Quality decisions made without appropriate authority
These are not minor issues.
They go to the core of GDP compliance and patient safety.
What a GDP Audit Should Really Do
A proper GDP audit is not just about checking documents.
It should help a business understand:
- Whether its systems reflect actual operations
- Whether responsibilities are clearly defined
- Whether records are accurate, complete and usable
- Whether risks are identified and controlled
- Whether escalation and CAPA processes are effective
- Whether staff are trained and operating correctly
- Whether the Responsible Person oversight is realistic
It should also highlight what needs to change before an inspection does.
Why Readiness Matters Before Inspection
MHRA inspections can be triggered by:
- New WDA(H) applications
- Changes to premises or key personnel
- Risk-based scheduling
- Potential GDP concerns or complaints
In some cases, inspections may be carried out with limited notice.
That means readiness should not start when inspection is announced.
It should already be in place.
Stag Global’s Approach
Stag Global does not act as a regulator.
We support businesses in understanding their current GDP position and strengthening it before regulatory pressure increases.
Our support focuses on:
- GDP audit and gap identification
- SOP and quality system review
- Responsible Person support structures
- Supplier and customer controls
- Training and role clarity
- CAPA and deviation processes
- Inspection readiness planning
The aim is simple.
To reduce uncertainty and avoid preventable compliance issues.
Why This Matters Now
With inspections continuing and compliance expectations evolving, businesses cannot rely on assumptions.
GDP readiness is not about perfection.
It is about control, clarity and evidence.
If your business is involved in medicines wholesale, now is the time to understand your position properly.
Need clarity on your GDP readiness?
Book a confidential consultation with Stag Global to review your systems, risks and next steps before inspection pressure increases.
